Hikma to market Ferinject for Vifor in MENA
This article was originally published in Scrip
Hikma Pharmaceuticals has entered into a licensing and distribution agreement to market Ferinject (ferric carboxymaltose), Vifor Pharma's intravenous iron deficiency treatment, in the Middle East and North African (MENA) region.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.